Trxade Group (OTCMKTS:TRXD) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

TRXD has been the topic of a number of other reports. Taglich Brothers restated a “speculative buy” rating on shares of Trxade Group in a research note on Friday, October 6th. Zacks Investment Research upgraded Trxade Group from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Thursday, December 7th.

Trxade Group (OTCMKTS TRXD) remained flat at $$0.45 during trading hours on Thursday. The company has a debt-to-equity ratio of -0.82, a quick ratio of 0.85 and a current ratio of 0.85. Trxade Group has a 52 week low of $0.22 and a 52 week high of $1.00. The firm has a market cap of $14.39, a price-to-earnings ratio of 22.50 and a beta of -0.80.

TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/04/trxade-group-trxd-upgraded-at-valuengine.html.

About Trxade Group

Trxade Group, Inc (Trxade) designs, develops, owns and operates a business-to-business Web-based marketplace focused on the United States pharmaceutical industry. The Company’s products and services include Trxade.com, InventoryRx.com, Pharmabayonline and RxGuru. Its services are distributed through its online platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with MarketBeat.com's FREE daily email newsletter.